Monopar Q1 net loss $2.4M; camsirubicin dose-escalation continues; Validive trial discontinued

Monopar Therapeutics

Net loss of $2.4M ($0.19/share) for Q1 2023, vs $2.5M ($0.19/share) in Q1 2022.
Cash, equivalents and short-term investments $11.7M as of March 31, 2023; runway through June 2024.
Camsirubicin Phase 1b enrolling 5th dose cohort (650 mg/m²); no drug-related cardiotoxicity observed to date.
Validive Phase 2b/3 VOICE trial discontinued after DSMB found it did not meet 15% efficacy threshold.
MNPR-101 RIT preclinical studies show high tumor uptake; FIH imaging study targeted by end of 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Monopar Therapeutics reported first quarter ended March 31, 2023 results: net income $2.4 million, EPS $0.19 per share.

Period: first quarter ended March 31, 2023
Net income: $2.4 million
EPS: $0.19 per share
Result: reported results

Exact text from the filing

Net loss for the first quarter of 2023 was $2.4 million or $0.19 per share

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Monopar Therapeutics filing history →

Source: SEC EDGAR

accession 0001654954-23-006120

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.